| Editorial Board |
|
vii | |
| Contributors |
|
ix | |
| Preface |
|
xxvii | |
|
|
| In Memoriam |
|
xxix | |
|
|
|
Optometry: Optical Coherence Technology in Glaucoma Diagnosis |
|
|
|
|
|
|
|
|
|
|
|
1 | (1) |
|
Optical coherence tomography retinal nerve fiber layer analysis in glaucoma diagnosis |
|
|
2 | (5) |
|
Optical coherence tomography macular analysis in glaucoma diagnosis |
|
|
4 | (3) |
|
Optical coherence tomography angiography in glaucoma diagnosis |
|
|
7 | (3) |
|
|
|
10 | (3) |
|
|
|
10 | (3) |
|
An Update on Neurodegenerative Disease for Eye Care Providers |
|
|
|
|
|
|
|
|
|
|
|
|
|
Introduction: neurodegenerative disease and the eye |
|
|
13 | (3) |
|
Neurodegenerative disease definition |
|
|
13 | (1) |
|
Varied pathophysiology of neurodegenerative diseases |
|
|
14 | (1) |
|
Prevalent visual and ocular associations of neurodegenerative disease |
|
|
14 | (2) |
|
Role of eye care providers in neurodegenerative disease |
|
|
16 | (1) |
|
Visual and ocular associations of neurodegenerative disease |
|
|
16 | (88) |
|
Eyelid function in neurodegenerative disease |
|
|
16 | (4) |
|
Anterior segment findings in neurodegenerative disease |
|
|
20 | (1) |
|
Posterior segment findings in neurodegenerative disease |
|
|
21 | (1) |
|
Afferent visual function in neurodegenerative disease |
|
|
22 | (82) |
|
Classification of seeding |
|
|
104 | (1) |
|
Impact of intravitreal injections on patient management |
|
|
105 | (2) |
|
Uses of intravitreal chemotherapy other than for vitreous seeds |
|
|
107 | (1) |
|
|
|
107 | (5) |
|
Pharmacokinetics of intravitreal melphalan |
|
|
112 | (1) |
|
Use of intravitreal topotecan |
|
|
113 | (1) |
|
Pharmacokinetics of intravitreal topotecan |
|
|
113 | (1) |
|
Stability of melphalan and topotecan |
|
|
114 | (1) |
|
|
|
115 | (1) |
|
|
|
115 | (1) |
|
|
|
116 | (3) |
|
Ophthalmic Pathology & Ocular Oncology: Applications of Plaque Brachytherapy in Posterior Segment Tumors: A Clinical Review |
|
|
|
|
|
|
|
|
|
|
|
119 | (1) |
|
|
|
120 | (1) |
|
|
|
121 | (3) |
|
Management of choroidal hemangioma |
|
|
122 | (1) |
|
Management of diffuse choroidal hemangioma |
|
|
122 | (2) |
|
Retinal capillary hemangioma |
|
|
124 | (1) |
|
Vasoproliferadve retinal tumors |
|
|
125 | (1) |
|
|
|
126 | (1) |
|
|
|
127 | (2) |
|
Limitations of plaque brachytherapy |
|
|
129 | (1) |
|
|
|
129 | (1) |
|
Methods for dose de-escalation |
|
|
129 | (1) |
|
|
|
130 | (3) |
|
Intraocular Tumors--Advances in Ophthalmic Pathology |
|
|
|
|
|
|
|
|
|
|
|
133 | (5) |
|
|
|
134 | (4) |
|
|
|
138 | (1) |
|
|
|
138 | (4) |
|
|
|
140 | (1) |
|
|
|
141 | (1) |
|
Primary vitreoretinal lymphoma |
|
|
142 | (3) |
|
Cytology and irnmunohistochemistry |
|
|
142 | (2) |
|
|
|
144 | (1) |
|
|
|
145 | (1) |
|
|
|
145 | (2) |
|
|
|
145 | (1) |
|
|
|
146 | (1) |
|
Adenoid Cystic Carcinoma of the Lacrimal Gland |
|
|
|
|
|
|
|
|
|
|
|
|
|
147 | (1) |
|
Significance (in-depth analysis) |
|
|
148 | (7) |
|
|
|
148 | (1) |
|
|
|
148 | (1) |
|
|
|
148 | (2) |
|
|
|
150 | (1) |
|
|
|
150 | (5) |
|
|
|
155 | (1) |
|
|
|
155 | (1) |
|
|
|
156 | (3) |
|
Cataract & Refractive Surgery: Micro-Invasive Glaucoma Surgery |
|
|
|
|
|
|
|
|
|
159 | (1) |
|
Significance and current relevance |
|
|
160 | (2) |
|
IStent trabecular micro-bypass stent |
|
|
162 | (1) |
|
|
|
163 | (2) |
|
Goniotomy-assisted trabeculotomy |
|
|
165 | (1) |
|
|
|
166 | (1) |
|
|
|
167 | (1) |
|
|
|
167 | (1) |
|
|
|
168 | (1) |
|
|
|
169 | (1) |
|
|
|
169 | (1) |
|
|
|
170 | (1) |
|
|
|
170 | (1) |
|
|
|
171 | (4) |
|
|
|
172 | (3) |
|
|
|
|
Artificial Intelligence in Retina |
|
|
|
|
|
|
|
|
|
Background and introduction |
|
|
175 | (1) |
|
Overview of artificial intelligence |
|
|
176 | (2) |
|
Evaluating deep learning algorithms |
|
|
178 | (1) |
|
|
|
179 | (2) |
|
Age-related macular degeneration |
|
|
181 | (1) |
|
|
|
182 | (1) |
|
|
|
183 | (1) |
|
|
|
184 | (3) |
|
|
|
184 | (3) |
|
Retina in the Age of COVID-19 |
|
|
|
|
|
|
|
|
|
|
|
187 | (1) |
|
|
|
188 | (1) |
|
General cleaning and hygiene |
|
|
188 | (1) |
|
Personal protective equipment |
|
|
188 | (1) |
|
|
|
189 | (1) |
|
Care in an active pandemic |
|
|
189 | (6) |
|
|
|
189 | (3) |
|
Precautions for procedures |
|
|
192 | (1) |
|
|
|
192 | (1) |
|
Precautions for laser procedures |
|
|
193 | (1) |
|
Scheduling follow-up visits |
|
|
193 | (1) |
|
Patients with positive screening or testing for COVID-19 |
|
|
194 | (1) |
|
Care after immediate pandemic restrictions are lifted |
|
|
195 | (2) |
|
Continued screening and scheduling precautions |
|
|
195 | (1) |
|
Day of appointment precautions |
|
|
195 | (1) |
|
Performing elective surgery |
|
|
196 | (1) |
|
Operating room precautions |
|
|
197 | (1) |
|
|
|
197 | (1) |
|
|
|
198 | (3) |
|
|
|
198 | (3) |
|
Diagnostic and Treatment Update on Sickle Cell Retinopathy |
|
|
|
|
|
|
|
|
|
|
|
201 | (1) |
|
|
|
202 | (1) |
|
|
|
202 | (1) |
|
|
|
203 | (2) |
|
|
|
205 | (1) |
|
|
|
206 | (4) |
|
Optical coherence tomography |
|
|
207 | (1) |
|
Optical coherence tomography angiography |
|
|
207 | (2) |
|
Ultra-wide fluorescein angiography |
|
|
209 | (1) |
|
|
|
210 | (2) |
|
|
|
210 | (1) |
|
|
|
210 | (1) |
|
Anti-vascular endothelial growth factor |
|
|
211 | (1) |
|
|
|
212 | (1) |
|
|
|
212 | (1) |
|
|
|
213 | (5) |
|
Glaucoma: Glaucoma Surgery: Which Surgery to Pick for Your Patient? |
|
|
|
|
|
|
|
|
|
218 | (1) |
|
|
|
218 | (1) |
|
|
|
219 | (1) |
|
When not to opt for subconjunctival surgery? |
|
|
219 | (1) |
|
Nonpenetrating glaucoma surgery |
|
|
219 | (3) |
|
|
|
222 | (1) |
|
XEN Gel Implant (Allergan Inc, Irvine, CA, USA) |
|
|
222 | (1) |
|
Preserflo Microshunt (Santen Pharmaceutical Co Ltd, Osaka, Japan) |
|
|
223 | (1) |
|
|
|
223 | (1) |
|
Cyclodestructive procedures |
|
|
224 | (1) |
|
Schlemm canal-based procedures |
|
|
225 | (6) |
|
Selective laser trabeculoplasty |
|
|
225 | (1) |
|
Schlemm canal-based microinvasive glaucoma surgery |
|
|
226 | (5) |
|
|
|
231 | (1) |
|
CyPass (Alcon, Fort Worth, TX, USA) |
|
|
231 | (1) |
|
|
|
231 | (8) |
|
Patients with very advanced disease |
|
|
231 | (1) |
|
Patients with very high intraocular pressure |
|
|
232 | (1) |
|
Patients with angle-closure glaucoma |
|
|
232 | (1) |
|
|
|
233 | (1) |
|
Primary angle-closure glaucoma |
|
|
233 | (1) |
|
Patients with neovascular glaucoma |
|
|
234 | (1) |
|
Reoperation after failed glaucoma surgery |
|
|
234 | (2) |
|
Current relevance and future avenues |
|
|
236 | (3) |
|
|
|
239 | (2) |
|
|
|
241 | (4) |
|
|
|
241 | (4) |
|
Ocular Blood Flow as It Relates to Race and Disease on Glaucoma |
|
|
|
|
|
|
|
Alice C. Verticchio Vercellin |
|
|
|
|
|
|
|
|
245 | (1) |
|
|
|
246 | (12) |
|
Racial disparities in glaucoma |
|
|
248 | (1) |
|
Mechanisms behind racial disparities in glaucoma |
|
|
248 | (10) |
|
|
|
258 | (1) |
|
|
|
259 | (1) |
|
|
|
259 | (4) |
|
|
|
259 | (4) |
|
Neuro-ophthalmology: Glaucoma as a Neurodegenerative Disease: A Clinician Perspective |
|
|
|
|
|
|
|
|
|
263 | (1) |
|
Is glaucoma a neurodegenerative disease? |
|
|
264 | (1) |
|
Sick eye comes with a sick brain |
|
|
264 | (2) |
|
Common clinical characteristics between glaucoma and neurodegenerative disease |
|
|
266 | (1) |
|
Overlapping pathophysiology between glaucoma and other neurodegenerative disease |
|
|
267 | (2) |
|
|
|
267 | (1) |
|
Oxidative stress and mitochondrial dysfunction |
|
|
267 | (1) |
|
Dysregulation of calcium dependent process |
|
|
268 | (1) |
|
Alterations of autophagy machinery |
|
|
268 | (1) |
|
|
|
268 | (1) |
|
|
|
269 | (1) |
|
Glaucoma and cerebrospinal fluid |
|
|
269 | (1) |
|
|
|
269 | (1) |
|
|
|
270 | (1) |
|
|
|
270 | (5) |
|
|
|
271 | (4) |
|
Neuro-Ophthalmologic Manifestations of Novel Coronavirus |
|
|
|
|
|
|
|
|
|
275 | (1) |
|
|
|
276 | (8) |
|
Neuro-ophthalmic presentations |
|
|
276 | (6) |
|
|
|
282 | (2) |
|
|
|
284 | (1) |
|
|
|
285 | (1) |
|
|
|
285 | (4) |
|
|
|
285 | (4) |
|
Cornea and External Diseases: Advances in Endothelial Keratoplasty Surgery |
|
|
|
|
|
|
|
|
|
|
|
289 | (1) |
|
|
|
290 | (8) |
|
|
|
290 | (3) |
|
Descemet stripping endothelial keratoplasty |
|
|
293 | (2) |
|
Descemet's membrane endothelial keratoplasty |
|
|
295 | (3) |
|
Descemetorhexis without endothelial keratoplasty |
|
|
298 | (1) |
|
Relevance and future avenues |
|
|
298 | (3) |
|
|
|
301 | (1) |
|
|
|
302 | (5) |
|
|
|
302 | (5) |
|
Update in the Management of Keratoconus |
|
|
|
|
|
|
|
|
|
307 | (3) |
|
|
|
310 | (3) |
|
Spectacles and contact lenses |
|
|
313 | (4) |
|
|
|
315 | (2) |
|
Intrastromal corneal ring segments |
|
|
317 | (2) |
|
|
|
319 | (1) |
|
Deep anterior lamellar keratoplasty |
|
|
320 | (1) |
|
|
|
320 | (1) |
|
|
|
321 | (4) |
|
|
|
321 | (4) |
|
Update on Refractive Surgery |
|
|
|
|
|
|
|
|
|
|
|
325 | (1) |
|
Significance and in-depth analysis of the topic |
|
|
326 | (6) |
|
Corneal refractive surgery |
|
|
326 | (2) |
|
Intraocular refractive surgery |
|
|
328 | (2) |
|
|
|
330 | (2) |
|
Current relevance and future avenues to investigate the topic |
|
|
332 | (4) |
|
Management of higher-order aberrations: wavefront-optimized, wavefront-guided, and topography-guided laser ablation |
|
|
332 | (1) |
|
Advances in refractive lenticule surgery |
|
|
333 | (1) |
|
Accommodative intraocular lens |
|
|
334 | (2) |
|
|
|
336 | (1) |
|
|
|
337 | (4) |
|
|
|
337 | (4) |
|
Oculoplastics: Xanthelasma Palpebrarum: An Oculoplastic Viewpoint of Optimal Treatment |
|
|
|
|
|
|
|
|
|
341 | (1) |
|
Significance (in-depth analysis) |
|
|
342 | (8) |
|
|
|
342 | (1) |
|
|
|
343 | (6) |
|
Surgical or laser treatment |
|
|
349 | (1) |
|
|
|
350 | (2) |
|
|
|
350 | (1) |
|
Nasal lower eyelid-primary |
|
|
351 | (1) |
|
Lesion extending to temporal lower lid |
|
|
352 | (1) |
|
Extensive lower lid lesions |
|
|
352 | (1) |
|
|
|
352 | (1) |
|
|
|
353 | (1) |
|
|
|
353 | (5) |
|
Refractive Error Changes Associated with Eyelid Weight Placement |
|
|
|
|
|
|
|
|
|
358 | (1) |
|
|
|
359 | (8) |
|
Efficacy of upper eyelid weight placement |
|
|
359 | (1) |
|
|
|
360 | (1) |
|
|
|
360 | (1) |
|
Complications of upper eyelid loading |
|
|
360 | (1) |
|
|
|
360 | (7) |
|
Relevance and future avenues |
|
|
367 | (2) |
|
|
|
368 | (1) |
|
Cost of platinum versus gold |
|
|
368 | (1) |
|
|
|
369 | (1) |
|
|
|
369 | (1) |
|
|
|
370 | (3) |
|
|
|
371 | (1) |
|
|
|
371 | (2) |
|
Refractive Change after Upper Eyelid Surgery |
|
|
|
|
|
|
|
|
|
|
|
373 | (2) |
|
|
|
375 | (1) |
|
|
|
376 | (1) |
|
|
|
377 | (1) |
|
|
|
377 | (2) |
|
|
|
378 | (1) |
|
Canalicular Stenosis Secondary to Chemotherapeutic Agents |
|
|
|
|
|
|
|
|
|
|
|
379 | (1) |
|
Chemotherapeutic agents known to cause canalicular stenosis |
|
|
380 | (2) |
|
|
|
380 | (1) |
|
|
|
381 | (1) |
|
|
|
381 | (1) |
|
Significance of epiphora secondary to canalicular abnormality |
|
|
382 | (1) |
|
Management of canalicular stenosis |
|
|
382 | (4) |
|
|
|
386 | (1) |
|
|
|
386 | (5) |
|
|
|
387 | (4) |
|
Uveitis: Optical Coherence Tomography Angiography in White Dot Syndromes |
|
|
|
|
|
|
|
|
|
|
|
391 | (1) |
|
|
|
392 | (1) |
|
Cross-sectional and en face visualizations of the posterior circulation |
|
|
393 | (1) |
|
Birdshot chorioretinopathy |
|
|
394 | (1) |
|
Multiple evanescent white dot syndrome |
|
|
395 | (1) |
|
Punctate inner choroiditis |
|
|
396 | (1) |
|
|
|
397 | (1) |
|
Acute posterior multifocal placoid pigment epitheliopathy |
|
|
398 | (1) |
|
Acute zonal occult outer retinopathy |
|
|
399 | (1) |
|
|
|
400 | (1) |
|
Relevance and future avenues |
|
|
400 | (1) |
|
|
|
401 | (1) |
|
|
|
401 | |
Lisainfo e-raamatute kohta